Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Janss, Cindy Levow, E. Bernhard, R. Muschel, W. Mckenna, L. Sutton, P. Phillips (1998)
Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.Experimental cell research, 243 1
(2003)
Phase II evaluation of CKD-602, a comptothecin analog administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer
C. Gomez-Manzano, M. Alonso, W. Yung, F. McCormick, D. Curiel, F. Lang, Hong Jiang, B. Bekele, Xian Zhou, R. Alemany, J. Fueyo (2006)
Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of IrinotecanClinical Cancer Research, 12
O. Michielin, E. Udry, D. Périard, O. Matzinger, J. Lobrinus, R. Stupp (2004)
Irinotecan-induced interstitial pneumonia.The Lancet. Oncology, 5 5
Gottlieb Ja, A. Guarino, Callahan Jb, Oliverio Vt, Block Jb (1970)
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).Cancer chemotherapy reports, 54 6
E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frénay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. Rodier, L. Vernillet, J. Armand (2003)
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.Annals of oncology : official journal of the European Society for Medical Oncology, 14 4
(2002)
Phase I trial of CKD-602, a novel camptothecin derivative, in patients with advanced solid tumor
C. Djuzenova, Teresa Güttler, S. Berger, A. Katzer, M. Flentje (2008)
Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatmentCancer Biology & Therapy, 7
J. Vredenburgh, A. Desjardins, J. Herndon, J. Dowell, D. Reardon, J. Quinn, J. Rich, S. Sathornsumetee, S. Gururangan, Melissa Wagner, D. Bigner, A. Friedman, H. Friedman (2007)
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant GliomaClinical Cancer Research, 13
R. Stupp, Warren Mason, M. Bent, M. Weller, B. Fisher, M. Taphoorn, K. Bélanger, A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, Robert Janzer, Samuel Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. Cairncross, E. Eisenhauer, R. Mirimanoff (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.The New England journal of medicine, 352 10
Eun Kim, Rae Lee, J. Suh, Sang‐Seop Han, Joon-Kyum Kim (2003)
Safety Pharmacology of CKD-602, a Novel Anticancer AgentArzneimittelforschung, 53
E. Jonsson, S. Dhar, Bengt Jönsson, Peter Nygren, Wilhelm Graf, Rolf Larsson (2000)
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.European journal of cancer, 36 16
S. Jew, Geonjoong Kim, Hyun-Jai Kim, E. Roh, H. Park (2010)
Synthesis and Antitumor Activity of Camptothecin AnaloguesChemInform, 23
P. D'Arpa, Chris Beardmore, Leroy Liu (1990)
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.Cancer research, 50 21
J. Fassberg, J. Fassberg, V. Stella (1992)
A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues.Journal of pharmaceutical sciences, 81 7
Jun-Hee Lee, Ju-Mong Lee, Joon-Kyum Kim, S. Ahn, Sangjin Lee, M. Kim, S. Jew, Jae-Gab Park, C. Hong (1998)
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitorArchives of Pharmacal Research, 21
M. Bissery, P. Vrignaud, F. Lavelle, Chabot Gg (1996)
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in miceAnti-Cancer Drugs, 7
H. Friedman, S. Keir, P. Houghton (2003)
The emerging role of irinotecan (CPT‐11) in the treatment of malignant glioma in brain tumorsCancer, 97
J. Lee, J. Lee, K. Lim, J. Kim, S. Ahn, Y. Bang, C. Hong (2000)
Preclinical and Phase I Clinical Studies with Ckd‐602, a Novel Camptothecin DerivativeAnnals of the New York Academy of Sciences, 922
N. Ishii, D. Maier, A. Merlo, M. Tada, Y. Sawamura, A. Diserens, Erwin Meir (1999)
Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.Brain Pathology, 9
D. Reardon, J. Quinn, J. Rich, S. Gururangan, J. Vredenburgh, J. Sampson, J. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, J. Herndon, J. Dowell, M. Affronti, S. Jackson, Deborah Allen, K. Ziegler, S. Silverman, C. Bohlin, A. Friedman, D. Bigner, H. Friedman (2004)
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.Neuro-oncology, 6 2
P. O'Connor, J. Jackman, Insoo Bae, Timothy Myers, S. Fan, M. Mutoh, D. Scudiero, A. Monks, E. Sausville, J. Weinstein, S. Friend, A. Fornace, K. Kohn (1997)
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.Cancer research, 57 19
L. Feun, A. Marini, H. Landy, A. Markoe, D. Heros, C. Robles, C. Herrera, N. Savaraj (2007)
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumorsJournal of Neuro-Oncology, 82
G. Klautke, M. Schütze, I. Bombor, R. Benecke, J. Piek, Rainer Fietkau (2006)
Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiformeJournal of Neuro-Oncology, 77
C. Kollmannsberger, K. Mross, A. Jakob, Lothar Kanz, C. Bokemeyer (1999)
Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical ExperienceOncology, 56
C. Moertel, Schutt Aj, R. Reitemeier, R. Hahn (1972)
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.Cancer chemotherapy reports, 56 1
S. Nakatsu, Seiji Kondo, Y. Kondo, D. Yin, J. Peterson, R. Kaakaji, T. Morimura, H. Kikuchi, J. Takeuchi, G. Barnett (1997)
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11Cancer Chemotherapy and Pharmacology, 39
F. Muggia, P. Creaven, H. Hansen, M. Cohen, Selawry Os (1972)
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.Cancer chemotherapy reports, 56 4
J. Jung, Sang-Hyun Song, Tae-Young Kim, Jung-Hyun Park, H. Jong, S. Im, Tae-You Kim, Y. Bang, N. Kim (2006)
The synergism between Belotecan and cisplatin in gastric cancer.Cancer research and treatment : official journal of Korean Cancer Association, 38 3
E. Morandi, C. Severini, Daniele Quercioli, Giovanni D'Ario, S. Perdichizzi, M. Capri, G. Farruggia, M. Mascolo, W. Horn, M. Vaccari, R. Serra, A. Colacci, P. Silingardi (2008)
Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell linesMolecular Cancer, 7
R. Mathijssen, W. Loos, J. Verweij, A. Sparreboom (2002)
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.Current cancer drug targets, 2 2
Yinglin Wang, Shaojun Zhu, T. Cloughesy, L. Liau, P. Mischel (2004)
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibitionOncogene, 23
M. Wall, M. Wani, C. Cook, K. Palmer, A. McPhail, G. Sim (1966)
Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2Journal of the American Chemical Society, 88
Joyce Thompson, E. George, C. Poquette, P. Cheshire, L. Richmond, S. Graaf, M. Ma, C. Stewart, P. Houghton (1999)
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 11
Y. Matsumoto, T. Fujiwara, Y. Honjo, N. Sasaoka, T. Tsuchida, S. Nagao (1993)
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.Journal of surgical oncology, 53 2
CKD-602 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, belotecan) is a synthetic water-soluble camptothecin derivative and topoisomerase inhibitor that has been shown to have clinical anticancer effect against ovarian and lung cancer. We studied its anticancer effects on four human glioma cell lines, U87 MG, U343 MG, U251 MG and LN229. Cell viability was quantified by a modified 2-(2-methoxy-4-nitropheyl)-3-(4-nitropheyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt and significant time- and dose-dependent cytotoxicity was observed in all cell lines. Susceptibility to CKD-602 at 48 h after treatment varied among the four cell lines and their IC50 value was as follows: 9.07 nM (95% CI 0.18-37.42) for LN229, 14.57 nM (95% CI 0.86-47.33) for U251 MG, 29.13 nM (95% CI 0.35-101.23) for U343 MG, and 84.66 nM (95% CI 34.63-148.25) for U87 MG. CKD-602 induced cell cycle arrest at G2 phase and produced antiproliferative activity and apoptosis in all cell lines. Thus, CKD-602 showed a significant anticancer effect on glioma cells in vitro and is a promising candidate for further studies on malignant gliomas.
Oncology Reports – Spandidos Publications
Published: Jun 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.